论文部分内容阅读
目的 观察川芎嗪对 2型糖尿病病人血浆纤溶酶原激活抑制剂 1(PAI 1)活性水平的影响。方法 6 0例 2型糖尿病病人随机分为治疗组和对照组 ,分别给予川芎嗪 (12 0mg/d)和生理盐水静滴 ,2 0d为 1个疗程。治疗前后测定PAI 1。结果 两组病人治疗后血浆PAI 1活性水平均有下降 ,治疗组下降显著 ,两组相比差异有显著意义 (P <0 0 1)。结论 川芎嗪可降低 2型糖尿病病人血浆PAI 1活性水平。
Objective To observe the effect of ligustrazine on plasma plasminogen activator inhibitor 1 (PAI 1) activity in type 2 diabetic patients. Methods Sixty patients with type 2 diabetes mellitus were randomly divided into treatment group and control group, which were given tetramethylpyrazine (120 mg / d) and saline intravenously respectively, and received a course of treatment for 20 days. PAI 1 before and after treatment. Results After treatment, plasma PAI 1 activity decreased in both groups, and the treatment group decreased significantly. There was significant difference between the two groups (P <0.01). Conclusion Tetramethylpyrazine can reduce plasma PAI 1 activity in type 2 diabetic patients.